ArticleKleinrok Z, Jagiełlłlo-Wójtowicz E, Sieklucka-Dziuba M.
Arch Immunol Ther Exp (Warsz). 1977;25(6):829-37.
It was found that fluorostigmine (DFP) in doses 0-4 mg/kg i.p. reduced significantly tryptophan pyrolase activity in mouse liver homogenates.se liver homogenates 120 and 180 min after the administration of the drug. On the other hand, fluorostigmine administered in doses 0-8 mg/kg i.p. increases the activity of the enzyme studied at 30 and 60 min after the injection. DFP (0.4 mg/kg i.p.) given in combination with atropine (10 mg/kg i.p.) causes a significant increase in enzyme activity determined 30, 60, 120 and 180 min after the administration of the drug. Toxogonine (in doses 5 mg/kg s.c.) given together with DFP (0.4 mg/kg i.p.) intensifies the activity of tryplophan pyrolase at 180 min after their administration. Simultaneous treatment with toxogonine (5 mg/kg s.c.), atropine (10 mg/kg i.p.) and DFP (0.4 MG/KG I.P.) reduced significantly the activity of the enzyme studied at all time of determination. Moreover, the experiment in vitro showed that DFP in concentrations of 4x10(-9) M; 8X10(-9) M; 1.6X10(-8) M and 3.2x10(-8) M increased tryptophan pyrolase activity in mouse liver homogenates.